The association of telomere length with substance use disorders: systematic review and meta-analysis protocol.
Meta-analysis
Substance use disorders
Systematic review
Telomere length
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
01 12 2019
01 12 2019
Historique:
received:
06
05
2019
accepted:
15
10
2019
entrez:
3
12
2019
pubmed:
4
12
2019
medline:
17
9
2020
Statut:
epublish
Résumé
The present protocol was designed for a systematic review and meta-analysis aimed at determining the association of telomere length with substance use disorders with the exclusion of nicotine addiction, and to identify potential moderators of the effect of telomere length. Such methodological information may provide guidance to improve the quality of future research on this important topic. Potential studies will be identified through electronic databases (PubMed/MEDLINE, EMBASE, PsycINFO, and Web of Science) up from inception onwards. The inclusion criteria will include published or unpublished observational studies (cohort, case-control, and cross-sectional studies) reporting telomere length in adult patients with substance use disorder compared with a control group. Non-human studies or other study designs such as reviews, case-only, family-based, and/or population studies with only healthy participants will be excluded, as well as those focused solely on nicotine addiction. The main outcome will be telomere length in adults with substance use disorder (primary) and, specifically, in those with alcohol use disorder (secondary). Two investigators will independently evaluate the preselected studies for possible inclusion and will extract data following a standardized protocol. Disagreements will be resolved by consensus. The risk of bias of all included studies will be assessed using the Newcastle-Ottawa Quality Assessment Scale for non-randomized studies. Data will be converted into standardized mean differences as effect size index, and random-effects models will be used for the meta-analysis. Cochran's Q statistic, I This systematic review will assess the association of telomere length with substance use disorders aside from nicotine addiction. PROSPERO registration number CRD42019119785.
Sections du résumé
BACKGROUND
The present protocol was designed for a systematic review and meta-analysis aimed at determining the association of telomere length with substance use disorders with the exclusion of nicotine addiction, and to identify potential moderators of the effect of telomere length. Such methodological information may provide guidance to improve the quality of future research on this important topic.
METHODS
Potential studies will be identified through electronic databases (PubMed/MEDLINE, EMBASE, PsycINFO, and Web of Science) up from inception onwards. The inclusion criteria will include published or unpublished observational studies (cohort, case-control, and cross-sectional studies) reporting telomere length in adult patients with substance use disorder compared with a control group. Non-human studies or other study designs such as reviews, case-only, family-based, and/or population studies with only healthy participants will be excluded, as well as those focused solely on nicotine addiction. The main outcome will be telomere length in adults with substance use disorder (primary) and, specifically, in those with alcohol use disorder (secondary). Two investigators will independently evaluate the preselected studies for possible inclusion and will extract data following a standardized protocol. Disagreements will be resolved by consensus. The risk of bias of all included studies will be assessed using the Newcastle-Ottawa Quality Assessment Scale for non-randomized studies. Data will be converted into standardized mean differences as effect size index, and random-effects models will be used for the meta-analysis. Cochran's Q statistic, I
DISCUSSION
This systematic review will assess the association of telomere length with substance use disorders aside from nicotine addiction.
SYSTEMATIC REVIEW REGISTRATION
PROSPERO registration number CRD42019119785.
Identifiants
pubmed: 31787100
doi: 10.1186/s13643-019-1199-x
pii: 10.1186/s13643-019-1199-x
pmc: PMC6886210
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
298Références
Int J Cancer. 2011 Aug 15;129(4):983-92
pubmed: 21351086
BMJ. 2014 Jul 08;349:g4227
pubmed: 25006006
Psychol Methods. 2008 Mar;13(1):31-48
pubmed: 18331152
J Int Med Res. 2016 Dec;44(6):1156-1173
pubmed: 28322101
Anxiety Stress Coping. 2017 May;30(3):264-272
pubmed: 27844481
Cell Mol Life Sci. 2015 Nov;72(21):4095-109
pubmed: 26190020
JAMA. 1999 Sep 15;282(11):1054-60
pubmed: 10493204
Transl Psychiatry. 2016 Jan 05;6:e709
pubmed: 26731446
Cell. 2001 Sep 21;106(6):661-73
pubmed: 11572773
Eur Neuropsychopharmacol. 2016 Jul;26(7):1241-7
pubmed: 27084304
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Psychosom Med. 2016 Sep;78(7):776-87
pubmed: 27359174
Res Synth Methods. 2014 Mar;5(1):60-78
pubmed: 26054026
BMJ. 2015 Jan 02;350:g7647
pubmed: 25555855
Depress Anxiety. 2015 Apr;32(4):229-38
pubmed: 25709105
Res Synth Methods. 2018 Sep;9(3):489-503
pubmed: 29989344
Biometrics. 2000 Jun;56(2):455-63
pubmed: 10877304
Schizophr Res. 2015 Jul;165(2-3):195-200
pubmed: 25975826
Neurosci Biobehav Rev. 2015 Aug;55:333-64
pubmed: 25999120
PLoS One. 2017 Jul 7;12(7):e0180687
pubmed: 28686726
Circ Cardiovasc Genet. 2015 Feb;8(1):82-90
pubmed: 25406241
Brain Behav Immun. 2016 May;54:158-169
pubmed: 26853993
Curr Opin Cell Biol. 2018 Jun;52:1-7
pubmed: 29253739
Nutrients. 2018 Dec 07;10(12):null
pubmed: 30544511
Psychol Methods. 2015 Sep;20(3):360-74
pubmed: 25110905
J Affect Disord. 2016 Feb;191:237-47
pubmed: 26688493
Biogerontology. 2019 Feb;20(1):1-16
pubmed: 30229407
BMJ. 2008 May 24;336(7654):1170-3
pubmed: 18497416
Oncotarget. 2017 Jul 4;8(27):45008-45019
pubmed: 28410238
J Gerontol A Biol Sci Med Sci. 2016 Aug;71(8):1069-73
pubmed: 27091133
Sci Rep. 2013;3:1542
pubmed: 23528991
Psychoneuroendocrinology. 2014 Apr;42:45-8
pubmed: 24636500
Front Mol Neurosci. 2018 May 16;11:160
pubmed: 29867352
World J Biol Psychiatry. 2018;19(sup2):S2-S20
pubmed: 28000540
Aging (Albany NY). 2016 Jan;8(1):3-11
pubmed: 26805432
J Psychiatr Res. 2017 Oct;93:64-71
pubmed: 28601667
Environ Res. 2017 Oct;158:480-489
pubmed: 28704792
Ageing Res Rev. 2018 Dec;48:11-20
pubmed: 30254001
J Alzheimers Dis. 2017;59(4):1459-1470
pubmed: 28777749
J Fam Psychol. 2014 Dec;28(6):967-72
pubmed: 25485673
Mol Neuropsychiatry. 2016 Jul;2(2):88-96
pubmed: 27429957
Stat Med. 2001 Jun 30;20(12):1771-82
pubmed: 11406840
Br J Psychiatry. 2015 May;206(5):371-8
pubmed: 25657360
Ageing Res Rev. 2016 Mar;26:37-52
pubmed: 26732034
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
J Hum Hypertens. 2017 Feb;31(2):99-105
pubmed: 27357526
Psychoneuroendocrinology. 2017 Sep;83:72-78
pubmed: 28599145
Science. 2015 Dec 4;350(6265):1193-8
pubmed: 26785477
Stat Med. 2019 Apr 15;38(8):1336-1342
pubmed: 30513552
Stat Med. 2003 Sep 15;22(17):2693-710
pubmed: 12939780
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:83-9
pubmed: 27346744
Physiol Rev. 2008 Apr;88(2):557-79
pubmed: 18391173
Br J Math Stat Psychol. 2014 Feb;67(1):30-48
pubmed: 23297709
J Psychiatr Res. 2016 Aug;79:50-56
pubmed: 27174400
J Pathol. 2011 Feb;223(3):410-6
pubmed: 21171086
J Affect Disord. 2015 Nov 1;186:241-8
pubmed: 26253905